If you have been reading about synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
=== Early work: 1924-1933 === In 1926, while at the University of Leipzig, Schoenheimer developed a method of synthesising peptides. From 1903 to 1909, Emil Fischer's scientific work had prompted the synthesis of many peptides, however there were limitations to his method. Fischer used a halogen acyl amino acid halide coupling method. A suitable method was needed, which involved an amino blocking group being removed by a nonhydrolyptic process. This method was first proposed by Rudolph Schoenheimer, as he utilised earlier findings by Michel Bergmann which demonstrated that with a mixture of hydrogen iodide and phosphonium iodide, p-toluenesulfonyl amino acids could be detosylated reductively. Schoenheimer used the azide coupling method introduced by Theodor Curtius, and the acid chloride method introduced by Emil Fischer in order to make several peptides. In 1929, Schoenheimer investigated how different sterols impacted cholesterol deposition in rabbits. It had been assumed that only plants were able to synthesize complex compounds whilst animals were forced to obtain these compounds indirectly from plants. It was assumed also that there would only small chemical changes were necessary when modifying these compounds to suit specific needs. Previous cholesterol-balance studies indicated that under specific conditions, animals could possess the ability to form cholesterol, as it has been discovered that sometimes negative balances are present in metabolic studies, wherein more sterol is excreted than consumed.
Paraxanthine (84%): Increases lipolysis, leading to elevated glycerol and free fatty acid levels in blood plasma. Theobromine (12%): Dilates blood vessels and increases urine volume. Theobromine is also the principal alkaloid in the cocoa bean (chocolate). Theophylline (4%): Relaxes smooth muscles of the bronchi, and is used to treat asthma. The therapeutic dose of theophylline, however, is many times greater than the levels attained from caffeine metabolism. 1,3,7-Trimethyluric acid is a minor caffeine metabolite. 7-Methylxanthine is also a metabolite of caffeine. Each of the above metabolites is further metabolized and then excreted in the urine. Caffeine can accumulate in individuals with severe liver disease, increasing its half-life. A 2011 review found that increased caffeine intake was associated with a variation in two genes that increase the rate of caffeine catabolism. Subjects who had this mutation on both chromosomes consumed 40 mg more caffeine per day than others. This is presumably due to the need for a higher intake to achieve a comparable desired effect, not that the gene led to a disposition for greater incentive of habituation. Caffeine can be easily protonated by strong acids to form corresponding caffenium salts. They are of interest because these cations are one of the main species in an acidic medium.
=== Pathologies detection === Alterations in the organization or polarity of the collagen fibrils can be signs of pathology,. In particular, the anisotropic alignment of collagen fibers allowed the discrimination of healthy dermis from pathological scars in skin. Also, pathologies in cartilage such as osteoarthritis can be probed by polarization-resolved SHG microscopy,. SHIM was later extended to fibro-cartilage (meniscus).
=== Neurological disease === FcRn is expressed at the blood–brain barrier (BBB), where it helps regulate the movement of IgG antibodies between the brain and peripheral circulation. Although IgG can enter the brain via passive diffusion in small amounts, FcRn primarily functions to transport IgG out of the CNS, contributing to immune surveillance and IgG clearance from the brain parenchyma. This efflux activity has implications for neuroinflammatory and neurodegenerative conditions, where pathogenic IgG accumulation in the CNS may be exacerbated by impaired FcRn function. Additionally, FcRn is being explored as a route for antibody-based drug delivery to the brain, using engineered Fc domains to engage FcRn-mediated transcytosis across the BBB.
However, several academic researchers became concerned that AI was no longer pursuing its original goal of creating versatile, fully intelligent machines. Beginning around 2002, they founded the subfield of artificial general intelligence (or "AGI"), which had several well-funded institutions by the 2010s. Deep learning began to dominate industry benchmarks in 2012 and was adopted throughout the field. For many specific tasks, other methods were abandoned. Deep learning's success was based on both hardware improvements (faster computers, graphics processing units, cloud computing) and access to large amounts of data (including curated datasets, such as ImageNet). Neural-network approaches also advanced natural language processing. In 2013, word2vec introduced efficient methods for learning distributed word representations. In 2014–2015, sequence-to-sequence and attention mechanisms advanced neural machine translation. Deep learning's success led to an enormous increase in interest and funding in AI. The amount of machine learning research (measured by total publications) increased by 50% in the years 2015–2019.
Sources: en.wikipedia.org
Watanabe et al. (2026) report evidence from the study of genomes of the Jōmon people indicative of their descent from Upper Paleolithic continental East Asian populations that settled the Japanese archipelago between 27,000 and 19,000 years ago, and evidence of cold adaptation in the Jōmon lineage. Evidence from the study of stone tool assemblages from the Buhais Rockshelter (United Arab Emirates) indicative of repeated occupation of the studied area between 210,000 and 16,000 years ago (including in the time of overall increased aridity of the Arabian Peninsula between 60,000 and 16,000 years ago) is presented by Bretzke et al. (2026). Evidence from the study of Natufian artefacts and rock art from the Sahout site and the neighbouring sites of Jebel Arnaan and Jebel Misma (Saudi Arabia), indicative of occupation of the studied area by communities interacting with people from the Fertile Crescent during the terminal Pleistocene and early Holocene, is presented by Shipton et al. (2026). Davin et al. (2026) report the discovery of clay ornaments from Natufian (late Epipalaeolithic) sites in Israel, interpreted as produced both by adults and by children, and representing the earliest known clay ornamental tradition outside of Europe. Evidence of importance of consumption of lizards and snakes in subsistence strategies of Natufian foragers from the El Wad site (Israel) is presented by Lev, Weinstein-Evron & Yeshurun (2026).
== Clinical significance == Myositis may cause thickening of the muscle fascicles. This may be detected with ultrasound scans. Muscle fascicle structure is a useful diagnostic tool for dermatomyositis. Myocytes towards the edges of the muscle fascicle are typically narrower, while those at the centre of the muscle fascicle are a normal thickness. Muscle fascicles may be involved in myokymia, although commonly only individual myocytes are involved.
An antifreeze is an additive which lowers the freezing point of a water-based liquid. An antifreeze mixture is used to achieve freezing-point depression for cold environments. Common antifreezes also increase the boiling point of the liquid, allowing higher coolant temperature. However, all common antifreeze additives also have lower heat capacities than water, and do reduce water's ability to act as a coolant when added to it. Because water has good properties as a coolant, water plus antifreeze is used in internal combustion engines and other heat transfer applications, such as HVAC chillers and solar water heaters. The purpose of antifreeze is to prevent a rigid enclosure from bursting due to expansion when water freezes. Commercially, both the additive (pure concentrate) and the mixture (diluted solution) are called antifreeze, depending on the context. Careful selection of an antifreeze can enable a wide temperature range in which the mixture remains in the liquid phase, which is critical to efficient heat transfer and the proper functioning of heat exchangers. Most if not all commercial antifreeze formulations intended for use in heat transfer applications include anti-corrosion and anti-cavitation agents (that protect the hydraulic circuit from progressive wear).
Robert Lax (1938), minimalist poet Ed Rice (1940), Beat Generation writer Walter Farley (1941), author of The Black Stallion and its many sequels Thomas Gallagher (1941), winner of a 1960 Edgar Award and National Book Award for Fiction finalist Gerald Green (1942), writer of Holocaust and The Last Angry Man, co-creator of NBC's The Today Show Richard de Mille* (1944), writer and investigative journalist, son of director Cecil B. DeMille Jack Kerouac* (1944), Beat Generation author of On the Road Leonard Koppett (1944), sportswriter; recipient of the J. G. Taylor Spink Award and the Curt Gowdy Media Award Walter Wager (1944), mystery writer whose book 58 Minutes was adapted into Die Hard 2 Herbert Gold (1946), Beat Generation novelist Daniel Hoffman (1947), poet; 22nd United States Poet Laureate Hiag Akmakjian (1948), author Allen Ginsberg (1948), Beat Generation poet; author of Howl Frederick Karl (1948), literary biographer famous for his work on Joseph Conrad Stanley Loomis (1948), American expatriate writer Charles Simmons (1948), author, winner of the 1965 William Faulkner Foundation Award for notable first novel Louis Simpson (1948), poet; winner of the 1964 Pulitzer Prize for Poetry John Clellon Holmes (1949), Beat Generation novelist, Go John Hollander (1950), poet, MacArthur Fellow and winner of the Bollingen Prize Richard Howard (1951), translator and winner of the Pulitzer Prize for Poetry Anthony Robinson (1953), English professor and novelist Ralph Schoenstein (1953), humorist Dan Wakefield (1955), novelist, journalist, screenwriter John J.
Establishing SIUT, Sukkur, was an innovative response to the need of the people of Sindh was planned in the year 2009. Rizvi anticipates the needs of his patients and responds accordingly. To make dialysis accessible, he conceptualized a network of satellite centers in various parts of Pakistan to save patients the trouble of commuting from far-flung areas of Sindh, southern parts of Punjab and Baluchistan to go for this procedure twice a week as far as Karachi. On 2 February 2012 Adibul Hasan Rizvi, Director Sindh Institute of Urology and Transplantation, along with a team of doctors and paramedical staff inaugurated SIUT-Chablani Medical Center Sukkur. Initially as a day care Dialysis Center with 16 Haemodialysis machines and OPD, which shall facilitate a large number of underprivileged patients of Upper Sindh, Lower Punjab & Baluchistan.
Sources: en.wikipedia.org
Bio-Synthesis, Inc. (BSI) is a biotechnology company headquartered in Lewisville, Texas. It is a provider of custom and catalog peptides, custom oligos, antibodies, organic synthesis, and analytical services. Biomedical researchers worldwide in universities, biotech companies, private clinics, and government agencies use products from Bio-Synthesis, Inc. in studies ranging from PCR diagnostics to cancer research and the Human Genome Project.
=== Template synthesis === The template synthesis method uses a nanoporous membrane template composed of cylindrical pores of uniform diameter to make fibrils (solid nanofiber) and tubules (hollow nanofiber). This method can be used to prepare fibrils and tubules of many types of materials, including metals, semiconductors and electronically conductive polymers. The uniform pores allow for control of the dimensions of the fibers so nanofibers with very small diameters can be produced through this method. However, a drawback of this method is that it cannot make continuous nanofibers one at a time.
== Other uses == Operation Snowcap (1987-1994) a U.S. counter-narcotics trafficking program Snowcaps (song), a 1999 song by Unwed Sailor Snow Cap (story) by Matthew S. Armstrong from the graphic novel anthology Flight, see List of volumes of Flight
A case in point is Castrovillari and its surrounding area, which in 1901 recorded a decrease of 7,190 people due to transoceanic emigration. The Nord (north) of Italy and the Mezzogiorno (the south) were at different levels of economic development. The Mezzogiorno was ignored under the Kingdom of Italy due to its backward status. In the late 19th century about 70% of the Mezzogiorno was illiterate; the government did not invest in education there. Owing to the Roman Question, until 1903 the Roman Catholic Church prohibited on pain of excommunication Catholic men from voting in Italian elections. The devout Catholics of Calabria tended to boycott elections, so the deputies were typically the products of the clientistic system, representing the aristocracy. They voted against money for education on the grounds that an educated population would demand changes that would threaten the traditional elite. Society in the late 19th century Calabria was dominated by an organized crime group known as 'Ndrangheta. Like the Mafia in Sicily and the Camorra in Campania, they formed a "parallel state" with significant power. Between 1901 and 1914 Calabrians began emigrating in large numbers, mostly for North and South America, peaking in 1905 at 62,690. On 28 December 1908, Calabria and Sicily were devastated by an earthquake and following tsunami, killing some 80,000. Within hours, ships of the British and Russian navies arrived to assist the survivors, while it took the Regia Marina two days to send a relief expedition from Naples.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.